NasdaqGS:ADPTLife Sciences
Adaptive Biotechnologies (ADPT) Stock Gains Little As MRD Growth Meets Wider Losses
Adaptive Biotechnologies stock barely budged after earnings, closing up just 0.2% around US$24.61. That muted move sits awkwardly against a quarter that put its core cancer minimal residual disease diagnostics front and center. Total revenue reached US$71.6m, while the company reported a net loss of US$39.8m that was heavily influenced by debt extinguishment and interest tied to the OrbiMed agreement.
The key takeaway for investors is margin and profit pressure alongside a strong MRD growth...